DENTSPLY SIRONA Toekomstige groei
Future criteriumcontroles 3/6
DENTSPLY SIRONA zal naar verwachting groeien in winst en omzet met respectievelijk 48.3% en 3.1% per jaar. De winst per aandeel zal naar verwachting groeien met 50.4% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 17% zijn.
Belangrijke informatie
48.3%
Groei van de winst
50.4%
Groei van de winst per aandeel
| Medical Equipment winstgroei | 17.3% |
| Inkomstengroei | 3.1% |
| Toekomstig rendement op eigen vermogen | 17.0% |
| Dekking van analisten | Good |
| Laatst bijgewerkt | 25 Oct 2024 |
Recente toekomstige groei-updates
Recent updates
DENTSPLY SIRONA (NASDAQ:XRAY) Hasn't Managed To Accelerate Its Returns
Oct 13
DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Looks Inexpensive But Perhaps Not Attractive Enough
Sep 25Is It Time To Consider Buying DENTSPLY SIRONA Inc. (NASDAQ:XRAY)?
Sep 05Is There An Opportunity With DENTSPLY SIRONA Inc.'s (NASDAQ:XRAY) 21% Undervaluation?
Aug 18Returns On Capital At DENTSPLY SIRONA (NASDAQ:XRAY) Have Hit The Brakes
Jul 11A Tough Macro Environment Makes Dentsply Sirona's Turnaround Even Harder
Jul 02Insufficient Growth At DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Hampers Share Price
Jun 11We Think DENTSPLY SIRONA (NASDAQ:XRAY) Can Stay On Top Of Its Debt
May 24Dentsply Sirona: I'm Buying The Pullback In This Medtech Leader
Apr 24Are Investors Undervaluing DENTSPLY SIRONA Inc. (NASDAQ:XRAY) By 47%?
Apr 22There's No Escaping DENTSPLY SIRONA Inc.'s (NASDAQ:XRAY) Muted Revenues
Mar 10Here's Why DENTSPLY SIRONA (NASDAQ:XRAY) Has A Meaningful Debt Burden
Feb 16DENTSPLY SIRONA (NASDAQ:XRAY) Has More To Do To Multiply In Value Going Forward
Jan 29DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Shares Could Be 28% Below Their Intrinsic Value Estimate
Jan 11Is It Too Late To Consider Buying DENTSPLY SIRONA Inc. (NASDAQ:XRAY)?
Nov 25These 4 Measures Indicate That DENTSPLY SIRONA (NASDAQ:XRAY) Is Using Debt Extensively
Nov 06Returns On Capital At DENTSPLY SIRONA (NASDAQ:XRAY) Paint A Concerning Picture
Oct 15An Intrinsic Calculation For DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Suggests It's 46% Undervalued
Sep 18DENTSPLY SIRONA (NASDAQ:XRAY) Has A Pretty Healthy Balance Sheet
Jul 31The Returns At DENTSPLY SIRONA (NASDAQ:XRAY) Aren't Growing
Jul 09A Look At The Fair Value Of DENTSPLY SIRONA Inc. (NASDAQ:XRAY)
Jun 20When Should You Buy DENTSPLY SIRONA Inc. (NASDAQ:XRAY)?
Jun 02Investors Don't See Light At End Of DENTSPLY SIRONA Inc.'s (NASDAQ:XRAY) Tunnel
May 15The Returns At DENTSPLY SIRONA (NASDAQ:XRAY) Aren't Growing
Apr 05Is DENTSPLY SIRONA (NASDAQ:XRAY) Using Too Much Debt?
Mar 07We Think DENTSPLY SIRONA (NASDAQ:XRAY) Can Stay On Top Of Its Debt
Nov 09Dentsply Sirona names Glenn Coleman as new CFO
Sep 22Dentsply Sirona hires Simon Campion as president, CEO
Aug 25Dentsply Sirona receives noncompliance notice from Nasdaq
Aug 16Dentsply Sirona: Weakening Fundamentals Outweigh 'Defensives' Argument
Jul 18Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 4,147 | 311 | 345 | N/A | 11 |
| 12/31/2025 | 3,994 | 246 | 294 | 402 | 14 |
| 12/31/2024 | 3,880 | 125 | 313 | 365 | 15 |
| 6/30/2024 | 3,896 | -185 | 364 | 527 | N/A |
| 3/31/2024 | 3,940 | -95 | 279 | 423 | N/A |
| 12/31/2023 | 3,965 | -132 | 228 | 377 | N/A |
| 9/30/2023 | 3,936 | -214 | 218 | 359 | N/A |
| 6/30/2023 | 3,936 | -1,025 | 198 | 334 | N/A |
| 3/31/2023 | 3,931 | -1,038 | 259 | 403 | N/A |
| 12/31/2022 | 3,922 | -950 | 368 | 517 | N/A |
| 9/30/2022 | 4,042 | -816 | 439 | 597 | N/A |
| 6/30/2022 | 4,135 | 345 | 499 | 660 | N/A |
| 3/31/2022 | 4,174 | 368 | 545 | 701 | N/A |
| 12/31/2021 | 4,231 | 411 | 515 | 657 | N/A |
| 9/30/2021 | 4,207 | 401 | 584 | 712 | N/A |
| 6/30/2021 | 4,062 | 370 | 634 | 748 | N/A |
| 3/31/2021 | 3,491 | 179 | 617 | 708 | N/A |
| 12/31/2020 | 3,339 | -73 | 562 | 649 | N/A |
| 9/30/2020 | 3,371 | -80 | 575 | 672 | N/A |
| 6/30/2020 | 3,438 | -48 | 524 | 623 | N/A |
| 3/31/2020 | 3,957 | 84 | 479 | 594 | N/A |
| 12/31/2019 | 4,022 | 256 | 516 | 639 | N/A |
| 9/30/2019 | 3,977 | 162 | 397 | 536 | N/A |
| 6/30/2019 | 3,944 | 105 | 337 | 502 | N/A |
| 3/31/2019 | 3,976 | -1,053 | 291 | 474 | N/A |
| 12/31/2018 | 3,986 | -1,011 | 312 | 500 | N/A |
| 9/30/2018 | 4,018 | -1,663 | 345 | 527 | N/A |
| 6/30/2018 | 4,098 | -1,601 | 398 | 565 | N/A |
| 3/31/2018 | 4,049 | -1,529 | N/A | 575 | N/A |
| 12/31/2017 | 3,993 | -1,550 | N/A | 602 | N/A |
| 9/30/2017 | 3,899 | -793 | N/A | 595 | N/A |
| 6/30/2017 | 3,844 | -791 | N/A | 584 | N/A |
| 3/31/2017 | 3,873 | 365 | N/A | 645 | N/A |
| 12/31/2016 | 3,745 | 430 | N/A | 563 | N/A |
| 9/30/2016 | 3,420 | 382 | N/A | 467 | N/A |
| 6/30/2016 | 3,115 | 374 | N/A | 474 | N/A |
| 3/31/2016 | 2,791 | 312 | N/A | 433 | N/A |
| 12/31/2015 | 2,674 | 251 | N/A | 497 | N/A |
| 9/30/2015 | 2,722 | 277 | N/A | 564 | N/A |
| 6/30/2015 | 2,782 | 268 | N/A | 551 | N/A |
| 3/31/2015 | 2,849 | 314 | N/A | 561 | N/A |
| 12/31/2014 | 2,923 | 323 | N/A | 560 | N/A |
| 9/30/2014 | 2,957 | 313 | N/A | 527 | N/A |
| 6/30/2014 | 2,953 | 317 | N/A | 506 | N/A |
| 3/31/2014 | 2,949 | 314 | N/A | 446 | N/A |
| 12/31/2013 | 2,951 | 313 | N/A | 418 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: Er wordt voorspeld dat XRAY de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 2.5% ).
Winst versus markt: Er wordt verwacht dat XRAY de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.
Hoge groeiwinsten: Er wordt verwacht dat XRAY binnen 3 jaar winstgevend zal worden.
Omzet versus markt: De omzet van XRAY ( 3.1% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 8.9% per jaar).
Hoge groei-inkomsten: De omzet van XRAY ( 3.1% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen XRAY zal naar verwachting over 3 jaar laag zijn ( 17 %).